The HMGN5 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout population derived from the Jurkat human T-lymphocyte line, engineered to disrupt the HMGN5 gene. This polyclonal format retains population heterogeneity and minimizes clonal artifacts, providing a robust system for loss?of?function studies in a cellular context relevant to T?cell biology and leukemia.
Jurkat cells were originally established from the peripheral blood of a 14-year-old male patient with T cell acute lymphoblastic leukemia (T-ALL). They serve as a widely utilized suspension model for investigating T cell receptor signaling, cytokine responses, and leukemogenesis. The cell line harbors known mutations in tumor suppressors such as PTEN and TP53, making it particularly suitable for studying oncogenic signal transduction and therapeutic interventions.
HMGN5 encodes a nucleosome?binding protein belonging to the high mobility group N family, which modulates higher?order chromatin structure to regulate transcription, DNA replication, and repair. It interacts directly with nucleosomes and histone H3, and its expression is controlled by the E2F1 transcription factor downstream of Wnt ligands and growth factor stimuli. HMGN5 promotes transcriptional activation of Cyclin D1, MMP9, ???catenin, and c?Myc, and functionally interfaces with p53, integrating signals from chromatin dynamics and cell proliferation pathways. Disruption of HMGN5 via CRISPR/Cas9 impairs chromatin remodeling and attenuates Wnt/???catenin and MAPK/ERK signaling, leading to reduced cell proliferation and migration.
In the Jurkat T-ALL background, HMGN5 knockout provides a physiologically relevant model to dissect the role of chromatin architectural proteins in leukemic transformation. Loss of HMGN5 disrupts the coordinated expression of pro?proliferative and pro?migratory genes, enabling detailed investigation of how nuclear structure influences oncogenic networks such as Wnt/???catenin and ERK1/2. This model is therefore valuable for elucidating mechanisms of T-ALL progression and for identifying vulnerabilities that may be exploited therapeutically.
Research applications encompass functional genomics of T-cell leukemia, cancer cell proliferation and metastasis assays, and drug target validation. Compatible experimental approaches include Western blotting and RT?qPCR for assessing HMGN5 and downstream target levels, MTT assays and flow cytometry for proliferation and cell cycle analysis, Transwell migration assays, transcriptome?wide profiling by RNA?seq, and co?immunoprecipitation to examine nucleosome and histone interactions. For additional technical information or support, please contact Ascent Research.
